Overall Assessment: Novo Nordisk is a MIXED opportunity for Ada Patient Finder. Their rare disease portfolio (growth hormone, hemophilia) presents strong opportunities with high undiagnosed rates and significant per-patient value. However, their dominant GLP-1/obesity franchise (Ozempic, Wegovy, Rybelsus) is NOT suitable for Patient Finder.
| Drug | Tier | Fit Score | USA Addressable Undiagnosed | Ada Revenue (1% capture) |
|---|---|---|---|---|
| Sogroya | TIER 1 | 9/10 | ~45,000 | $810K-$1.2M |
| Norditropin | TIER 2 | 7/10 | ~45,000 | $430K-$1.13M |
| Alhemo | TIER 2 | 7/10 | ~3,300 | $620K-$990K |
| Mim8 (pipeline) | TIER 2 | 8/10 | ~2,900 | $620K-$930K |
| Etavopivat (pipeline) | TIER 3 | 6/10 | ~26,000 | $720K-$2.16M |
| Ozempic | NO | 2/10 | N/A | Not suitable |
| Wegovy | NO | 2/10 | N/A | Not suitable |
| Rybelsus | NO | 2/10 | N/A | Not suitable |
Total Tier 1+2 Opportunity: $248M-$426M addressable | $2.5M-$4.2M at 1% capture | $12.4M-$21M at 5% capture
Indication: Once-weekly growth hormone for Growth Hormone Deficiency (GHD)
| Metric | USA | DACH | ROW |
|---|---|---|---|
| Total GHD Prevalence | ~120,000 (at-risk) | ~10,000-25,000 | ~500,000 |
| Undiagnosed Rate | ~90% | ~70% | ~85% |
| Drug-Addressable Undiagnosed | ~45,000 | ~10,500 | ~150,000 |
| Net Revenue/Patient/Year | $18,000-$27,000 | €15,000-€22,000 | Varies |
| PF Fee (10%) | $1,800-$2,700 | €1,500-€2,200 | Varies |
2024 Sales: DKK 4,993M (~$725M) for Rare Endocrine segment, +30% YoY
Source: Novo Nordisk 2024 Annual Report
Key Symptoms: Fatigue, poor exercise tolerance, increased abdominal fat, decreased muscle mass, depression, anxiety
Diagnostic Delay: Adult-onset GHD often undiagnosed for years; symptoms mimic aging, depression, metabolic syndrome
Key Finding: 25% of TBI survivors have undiagnosed GHD
Ada Surface Ability: HIGH - Symptom cluster (fatigue + weight gain + depression + muscle loss) is identifiable; can flag TBI/pituitary history
| Scenario | Annual Ada Revenue |
|---|---|
| 1% of addressable captured | $810,000 - $1,215,000 |
| 5% of addressable captured | $4,050,000 - $6,075,000 |
Indication: Once-daily subcutaneous prophylaxis for Hemophilia A/B
USA Hemophilia Prevalence: ~33,000 (22,000 Hem A, 5,000 Hem B)
Undiagnosed Mild Cases: ~20-30% = 6,600
Drug-Addressable: ~3,300 (mild undiagnosed + undertreated severe)
Net Revenue/Patient: $187,500-$300,000/year
PF Fee: $18,750-$30,000/patient
Approval: FDA Dec 2024; expanded July 2025 for non-inhibitor patients
Symptoms: Bleeding episodes, easy bruising, prolonged bleeding after injury/surgery
Diagnostic Delay: Severe cases diagnosed in infancy; mild cases often diagnosed 5-15 years late, sometimes only after surgical bleeding
Ada Surface Ability: MODERATE - Can flag bleeding symptom clusters and family history
Indication: Bispecific antibody for Hemophilia A (Phase 3, expected 2026 approval)
Indication: Daily growth hormone for GHD
Same addressable market as Sogroya (~45,000 undiagnosed adults). Bundle with Sogroya pitch - every GHD patient Ada identifies is a potential Norditropin or Sogroya patient.
Net Revenue/Patient: $12,000-$21,000/year
1% capture: $430K-$1.13M | 5% capture: $2.15M-$5.65M
Indication: Oral pyruvate kinase activator for Sickle Cell Disease (Phase 3)
USA SCD Prevalence: ~100,000-123,000
Undiagnosed: ~30% (~26,000-37,000) - gaps in immigrant populations, older adults
Timeline: Phase 3 HIBISCUS completion Dec 2026; approval expected 2027-2028
Recommendation: Monitor and revisit in 2027 as launch approaches
Fit Score: 2/10 | Ada Surface Ability: N/A (nothing to surface) | Company Motivation: None (supply-constrained)